SCHEMBL649987

SCHEMBL649987

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(S(N)(=O)=O)cc1)Cc1cccc(C(F)(F)F)c1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.41
CA1 P00915 8/20 0.40
CA2 P00918 8/20 0.40
CA12 O43570 7/20 0.40
CA9 Q16790 6/20 0.40
CA4 P22748 4/20 0.40
PTGS1 P23219 2/20 0.39
PTGS2 P35354 2/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.37
NR3C1 P04150 1/20 0.37
ELANE P08246 1/20 0.37
P2RX3 P56373 1/20 0.36
PDPK1 O15530 1/20 0.36
UBE2M P61081 1/20 0.36
DCUN1D1 Q96GG9 1/20 0.36
TRPV4 Q9HBA0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650105 0.91 C5AR1 (0.46) C5AR1MEN1KMT2AP2RX3UBE2M
SCHEMBL653132 0.87 C5AR1 (0.40) C5AR1CA1CA2CA12CA9
SCHEMBL649414 0.87 CA2 (0.41) C5AR1CA1CA2CA12CA9
SCHEMBL648462 0.86 CA1 (0.42) C5AR1CA1CA2CA12CA9
SCHEMBL5136743 0.86 C5AR1 (0.45) C5AR1MEN1KMT2AP2RX3UBE2M
SCHEMBL649773 0.86 C5AR1 (0.42) C5AR1CA1CA2CA12CA4
SCHEMBL1912982 0.86 TRPM8 (0.44) C5AR1PTGS1PTGS2PTGDR2
SCHEMBL651212 0.86 C5AR1 (0.39) C5AR1CA1CA2CA12CA9
SCHEMBL650800 0.86 C5AR1 (0.45) C5AR1CA1CA2CA12CA4
SCHEMBL651116 0.86 CRHR1 (0.41) C5AR1CA1CA2CA12CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed